SCO-101 mediates resensitization of irinotecan (SN38) resistant colorectal cancer cells

被引：0
|
作者：
Stenvang, Jan
Roest, Nicklas Lindland
Vestlev, Peter Michael
Hansen, Bo Rode
机构：
来源：
MOLECULAR CANCER THERAPEUTICS | 2021年 / 20卷 / 12期
关键词：
D O I：
10.1158/1535-7163.TARG-21-P077
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P077
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Re-sensitization of irinotecan/SN38 resistant colorectal cancer cells by SCO-101
    Stenvang, Jan
    Ambjorner, Sophie
    Sedighi, Khwajanezrabodin
    Vestlev, Peter Michael
    Saaby, Lasse
    Brodin, Birger
    Brunner, Nils
    CANCER RESEARCH, 2020, 80 (16)
  • [2] ATP Citrate Lyase Mediates Resistance of Colorectal Cancer Cells to SN38
    Zhou, Yunfei
    Bollu, Lakshmi Reddy
    Tozzi, Federico
    Ye, Xiangcang
    Bhattacharya, Rajat
    Gao, Guang
    Dupre, Elizabeth
    Xia, Ling
    Lu, Jia
    Fan, Fan
    Bellister, Seth
    Ellis, Lee M.
    Zhang Weihua
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (12) : 2782 - 2791
  • [3] Sensitization of docetaxel-resistant breast cancer cells to docetaxel by the VRAC modulator SCO-101
    Bagger, Sofie O.
    Drejer, Jorgen
    Bruenner, Nils
    Nielsen, Signe L.
    Christoffersen, Palle
    Stenvang, Jan
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [4] Synergistic and Antagonistic Antiproliferative Effects of Ribociclib (Lee011) and Irinotecan (SN38) on Colorectal Cancer Cells
    Huang, Chung-, I
    Huang, Yi-Kai
    Lee, Hui-Ming
    Chen, Jian-Han
    Su, Yu-Chieh
    Lin, Pai-Mei
    ANTICANCER RESEARCH, 2023, 43 (05) : 1933 - 1941
  • [5] ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases
    Candeil, L
    Gourdier, I
    Peyron, D
    Vezzio, N
    Copois, V
    Bibeau, F
    Orsetti, B
    Scheffer, GL
    Ychou, M
    Khan, QA
    Pommier, Y
    Pau, B
    Martineau, P
    Del Rio, M
    INTERNATIONAL JOURNAL OF CANCER, 2004, 109 (06) : 848 - 854
  • [6] The potential role of Alu Y in the development of resistance to SN38 (Irinotecan) or oxaliplatin in colorectal cancer
    Lin, Xue
    Stenvang, Jan
    Rasmussen, Mads Heilskov
    Zhu, Shida
    Jensen, Niels Frank
    Tarpgaard, Line S.
    Yang, Guangxia
    Belling, Kirstine
    Andersen, Claus Lindbjerg
    Li, Jian
    Bolund, Lars
    Brunner, Nils
    BMC GENOMICS, 2015, 16
  • [7] Evaluation of SN-38 PK profile in patients with RAS wild-type metastatic colorectal cancer treated with a combination of SCO-101 and FOLFIRI
    Schou, Jakob Hagen Vasehus
    Roest, Nicklas
    Ladekarl, Morten
    Hansen, Jens Bo Rode
    Hedtjaern, Maj
    Vestlev, Peter Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [8] The potential role of Alu Y in the development of resistance to SN38 (Irinotecan) or oxaliplatin in colorectal cancer
    Xue Lin
    Jan Stenvang
    Mads Heilskov Rasmussen
    Shida Zhu
    Niels Frank Jensen
    Line S Tarpgaard
    Guangxia Yang
    Kirstine Belling
    Claus Lindbjerg Andersen
    Jian Li
    Lars Bolund
    Nils Brünner
    BMC Genomics, 16
  • [9] Screening of 129 FDA approved anti-cancer drugs in colorectal cancer cell lines resistant to oxaliplatin or irinotecan (SN38).
    Stenvang, Jan
    Andreassen, Christine Hjorth
    Brunner, Nils
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [10] Sco-101 is a novel oral drug that reverses antiestrogen resistance in breast cancer cells
    Stenvang, Jan
    Madsen, Ida C. B.
    Hartfelt, Katrine
    Jandu, Haatisha
    Nielsen, Signe L.
    Christophersen, Palle
    Brunner, Nils
    CANCER RESEARCH, 2021, 81 (04)
12345